Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jan 12, 2010

Premium

Amarantus Therapeutics has appointed Vern Norviel to the position of corporate secretary. Norviel is a partner at Wilson Sonsini Goodrich & Rosati, where he leads the firm's patents and innovation counseling practice.

Norviel previously served as general counsel and corporate secretary of Perlegen Sciences, senior vice president and general counsel at Affymetrix, and partner at Townsend & Townsend & Crew in Palo Alto, Calif.


Anti-aging company Nu Skin Enterprises has named Stuart Kim to its scientific advisory board. Kim will provide insights on the molecular analysis of aging science, the firm said.

Kim is a professor at Stanford University in the departments of developmental biology and genetics. His recent research interests have focused on functional genomics and systems biology. Kim has produced DNA microarrays for C. elegans and used them to profile gene expression during development and aging.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.